The Biden administration is set to “temporarily” lift a Trump administration policy requiring women seeking abortion-inducing drug Mifepristone — also known as RU486 — to be administered in person by health professionals, allowing the pills to be disbursed via mail citing the coronavirus pandemic.
CBS News reported that acting FDA Commission Janet Woodcock informed the American College of Obstetrics and Gynecologists in a letter on Monday that her agency would allow providers in some states to “exercise enforcement discretion,” citing studies that dismissed any “serious safety concerns…occurring with medical abortion as a result of modifying the in-person dispensing requirement during the COVID-19 pandemic.”
Pro-life organization March for Life said of the move:
“With this action, the Biden administration has made it clear that it will prioritize abortion over women’s safety. Allowing unsupervised chemical abortions via telemedicine, without requiring timely access to medical care, will put women in grave danger.
“Data released in 2018 by the FDA shows thousands of adverse events caused by abortion pills, including 768 hospitalizations and 24 deaths since 2000. Chemical abortions should have more medical oversight not less.”